April 10, 2024
Expression Systems and Thomson recently teamed up to demonstrate how the combination of Expression Systems new ESF AdvanCD™ cell culture medium and Thomson Optimum Growth® flasks offers an effective solution for scaling up protein production utilizing baculovirus and insect cell expression platforms. In addition to highly consistent cell growth, exceptional expression levels were observed between various flask sizes and culture volumes, providing confidence in a robust and scalable platform.
To learn more, check out our recently published application note detailing the cultivation of Sf9 suspension cells using ESF AdvanCD chemically defined cell culture media together with Thomson Optimum Growth flasks.
October 5, 2023
EXPRESSION SYSTEMS INTRODUCES CHEMICALLY DEFINED INSECT CELL CULTURE MEDIUM FOR SUPERIOR PROTEIN EXPRESSION YIELDS
ESF AdvanCD™ is a 100% chemically defined, animal-origin-free, protein-free, serum-free insect cell culture medium for use in viral vector manufacturing, structural biology and other applications
DAVIS, California – Expression Systems, an Advancion company, today introduced a new, chemically defined cell culture medium that offers exceptional performance while improving the consistency and efficiency of gene therapy and other biologics manufacturing processes.
ESF AdvanCD™ cell culture medium is a proprietary formulation manufactured exclusively by Expression Systems, a leading global provider of specialty cell culture media formulations, cell lines, and contract services for the baculovirus expression platform. The ESF AdvanCD cell culture medium supports scalable baculovirus infection and protein expression in Spodoptera and Trichoplusia cell lines.
“ESF AdvanCD cell culture medium is the next generation of Expression Systems’ best-in-class product lines for developing and producing advanced therapies leveraging the productivity advantages of the BEVS platform,” said Dr. Thera Mulvania, President, Expression Systems. “The ESF AdvanCD media enables exceptional Sf9 growth and viability, and we see up to double the capacity for cell growth compared to other commercially available media, depending on your construct and culturing conditions.”
ESF AdvanCD media is offered as a ready-to-use liquid formulation, with no supplementation required. The formulation is adapted for use with Expression Systems’ Sf9 RV-Free rhabdovirus negative cell line for a fully compliant manufacturing platform. ESF AdvanCD Medium is manufactured by Expression Systems in compliance with 21 CFR 820 cGMP guidelines and produced in a facility that is ISO 13485-certified. Expression Systems also offers custom manufacturing services and process expertise to help optimize performance in individual customer applications.
Promo packs are now available for evaluation and include: four one-liter bottles of ESF AdvanCD media, one 20-ml bottle of VSA (Virus Stabilization Additive), and one vial of co-developed Sf9 cells. Visit with an Expression Systems expert at the upcoming Cell & Gene Meeting on the Mesa from October 8-10, in Carlsbad, California. To schedule a meeting with our team, click here: https://informaconnect.com/cell-gene-meeting-on-the-mesa/pone/login/
ABOUT Expression Systems
Founded in 1997, Expression Systems, now an Advancion company, is dedicated to supplying and servicing the cell culture and bio-industrial markets with innovative cell culture media formulations, as well as cell lines, molecular tools, reagents, and contract services. The company specializes in the baculovirus expression vector system (BEVS) and has deep expertise across the process from gene optimization to protein purification. Its well-characterized, high-performing line of insect cell culture media is recognized as the industry standard by structural biology researchers and biologics manufacturers to produce certain drug candidates, protein-based therapies, vaccines and gene therapies efficiently and cost-effectively. For more information, visit expressionsystems.com.
Follow Expression Systems on LinkedIn.
ABOUT ADVANCION
Advancion, formerly ANGUS Chemical Company, is a leading global producer of specialty ingredients and consumables for biotechnology, pharmaceutical, home and personal care, and other consumer-oriented and industrial markets. The Company is one of the world’s largest producers of life sciences buffers and other proprietary ingredients, providing high-performance products, best-in-class quality and guaranteed supply security for more than 80 years. Through Expression Systems, an Advancion company, the Company produces innovative cell culture media formulations, cell lines, molecular tools and reagents used in the development and commercial manufacturing of advanced therapies. Advancion operates three manufacturing facilities in the U.S. and Germany and serves its global customers through six regional Customer Application Centers located in Chicago, Illinois; Paris, France; São Paulo, Brazil; Singapore; Shanghai, China; and Mumbai, India. The Company is privately owned by Ardian and Golden Gate Capital, and is headquartered in Buffalo Grove, Illinois. For more information, visit advancionsciences.com.
Follow Advancion on LinkedIn.
June 28, 2023
EXPRESSION SYSTEMS LAUNCHES RHABDOVIRUS-FREE CELL LINE FOR DEVELOPMENT OF ADVANCED THERAPIES
The Sf9 RV-Free Insect Cell Line is adapted for growth in Expression Systems’ new ESF AdvanCD Chemically Defined Insect Cell Culture Medium with full traceability and documentation available
DAVIS, California – Expression Systems, an ANGUS company, and a leading global provider of specialty cell culture media formulations, cell lines, and contract services for the baculovirus expression platform, today announced early-access availability of its new rhabdovirus-free cell line for manufacturing advanced therapies.
The Sf9 RV-Free Insect Cell Line is a proven rhabdovirus-negative Sf9 cell line grown in suspension culture and adapted for optimized growth in Expression Systems’ new ESF AdvanCD Chemically Defined Insect Cell Culture Medium. The Sf9 RV-Free Insect Cell Line provides enhanced risk mitigation and productivity for producers of recombinant proteins, adeno-associated viruses (AAV) and virus-like particles (VLP).
“We are thrilled with the exceptional growth characteristics of Expression Systems’ Sf9 RV-Free Insect Cells with our new ESF AdvanCD Chemically Defined Insect Cell Culture Medium,” said Thera Mulvania, President, Expression Systems. “Sf9 RV-Free Cells cultured in ESF AdvanCD Medium demonstrate robust growth over several days with doubling times less than 24 hours. With a cell viability above 95 percent, and cell densities exceeding 25 x 106 cells/mL within 5 days, the obtainable cell density allows for a greater working range of growth and improved bioprocessing productivity.”
The Sf9 RV-Free Insect Cells were cloned by Expression Systems via single-cell printing and come with detailed protocols for optimal performance, as well as full traceability and documentation for regulatory filings. The Sf9 RV-Free Cells are currently available as a research cell bank with test lots of ESF AdvanCD Chemically Defined Insect Cell Culture Medium. A Master Cell Bank manufactured under GMP conditions and tested for adventitious agents will be available early 2024.
“ANGUS continues to invest in new innovations and new capacity that advance both the upstream development and downstream processing of novel biologics and advanced therapies,” said David Neuberger, ANGUS President and Chief Executive Officer. “Together, the new rhabdovirus-free cell line and chemically defined insect cell culture medium create a high-performance, next-generation AAV manufacturing platform that significantly expands our upstream offering for viral vaccine and gene therapy applications.”
The Sf9 RV-Free Cell Line is available exclusively from Expression Systems for research use only under a Limited Use Label License (“LULL”). A commercial license agreement must be purchased prior to use of the cell line, progeny, derivatives or products produced by the cell line in a clinical application or commercial purpose. Contact sales@expressionsystems.com or call +1 (877) 877-7421 for licensing details.
ABOUT EXPRESSION SYSTEMS
Founded in 1997, Expression Systems, now an ANGUS company, is dedicated to supplying and servicing the cell culture and bio-industrial markets with innovative cell culture media formulations, as well as cell lines, molecular tools, reagents, and contract services. The company specializes in the baculovirus expression vector system (BEVS) and has deep expertise across the process from gene optimization to protein purification. Its well-characterized, high-performing line of insect cell culture media is recognized as the industry standard by structural biology researchers and biologics manufacturers to produce certain drug candidates, protein-based therapies, vaccines and gene therapies efficiently and cost-effectively. For more information, visit expressionsystems.com.
Follow Expression Systems on LinkedIn.
ABOUT ANGUS
ANGUS is a leading global manufacturer and marketer of specialty ingredients and consumables for biotechnology, pharmaceutical, consumer and industrial applications. The Company innovates through its unique nitroalkane chemistries, including its flagship AMP™ (aminomethyl propanol) multifunctional additives and TRIS AMINO™ (tromethamine) buffers, which are produced at fully integrated, ISO 9001-certified manufacturing facilities in the United States and Germany. ANGUS serves its global customers through six regional Customer Application Centers located in Chicago, Illinois; Paris, France; São Paulo, Brazil; Singapore; Shanghai, China; and Mumbai, India. The Company is privately owned by Ardian and Golden Gate Capital, and is headquartered in Buffalo Grove, Illinois. For more information, visit angus.com.
Follow ANGUS on Facebook, Twitter, and LinkedIn.
###
May 4, 2023
ANGUS ANNOUNCES CORPORATE REBRANDING, WILL CHANGE NAME TO “ADVANCION”
New name and brand reflect Company’s strategic transformation into a leading global producer of specialty ingredients for Life Sciences, Personal Care and other essential markets
BUFFALO GROVE, Illinois – ANGUS Chemical Company (“ANGUS” or “Company”), the parent company of Expression Systems, today unveiled a new name and logo as part of an extensive corporate rebranding initiative. The Company, which has operated as ANGUS for more than 40 years, will rebrand and change its name to “Advancion.” The Advancion name reflects the significant transformation of the Company into a leading global producer of essential ingredients for the biotechnology, pharmaceutical, home and personal care, and other consumer-oriented and industrial markets.
“From material science to molecular biology, we are a company built on decades of precision and ingenuity. The high-quality, high-purity ingredients we develop and produce today are helping the world’s most essential industries address the emerging challenges of tomorrow,” said David Neuberger, President and CEO. “We are the same organization, ownership, leadership and team of dedicated employees. Our transition to the Advancion name and brand will more clearly represent who we are and what we do – a designer and producer of high-value consumables and ingredients that help enrich lives and enable our customers to advance the world.”
ANGUS, a portfolio company of Ardian and Golden Gate Capital, is one of the world’s largest suppliers of Life Sciences buffers and other proprietary chemistries. The Company’s specialty ingredients help improve product performance, quality, consistency, durability, stability and other important attributes in end-use formulations. Through its recent acquisition of Expression Systems, ANGUS also produces innovative cell culture media formulations, cell lines, molecular tools and reagents servicing high growth biologics segments including cell and gene therapies.
The Company’s transition to the new Advancion name and brand identity is targeted to be completed in August 2023. Initial elements of the Advancion brand evolution include a new logo design inspired by the multifunctionality and versatility of the Company’s unique ingredients and a fresh, modern color palette. In addition, a rebranding resource page is available on angus.com/rebranding to provide customers and suppliers with direct access to all communications, sample documents and frequently asked questions related to the brand transition, once they are available. Click here for a message from our CEO.
ABOUT ANGUS
ANGUS is a leading global manufacturer and marketer of specialty ingredients and consumables for biotechnology, pharmaceutical, consumer and industrial applications. The Company innovates through its unique nitroalkane chemistries, including its flagship AMP™ (aminomethyl propanol) multifunctional additives and TRIS AMINO™ (tromethamine) buffers, which are produced at fully integrated, ISO 9001-certified manufacturing facilities in the United States and Germany. ANGUS serves its global customers through six regional Customer Application Centers located in Chicago, Illinois; Paris, France; São Paulo, Brazil; Singapore; Shanghai, China; and Mumbai, India. The Company is privately owned by Ardian and Golden Gate Capital, and is headquartered in Buffalo Grove, Illinois. For more information, visit angus.com.
Follow ANGUS on Facebook, Twitter, and LinkedIn.
###
ANGUS ACQUIRES EXPRESSION SYSTEMS, LLC
FOR IMMEDIATE RELEASE
November 9, 2022
Expression Systems is a leading supplier of innovative cell culture media, baculovirus molecular reagents and cell lines used in advanced biological-based therapeutics
BUFFALO GROVE, Illinois and DAVIS, California – ANGUS Chemical Company (“ANGUS” or “Company”), a leading global manufacturer and marketer of specialty ingredients for Life Sciences and Industrial markets, today announced it has acquired Expression Systems, LLC (“Expression Systems”), a leading global manufacturer of cell culture media and related products and services. ANGUS is a portfolio company of Ardian and Golden Gate Capital.
Founded in 1997, Expression Systems is dedicated to supplying and servicing the baculovirus expression platform with innovative cell culture media formulations, as well as cell lines, molecular tools, reagents and contract services. Expression Systems operates from a central headquarters in Davis, California, and is cGMP-compliant and ISO 13485 certified for its manufacturing and research activities.
“The acquisition of Expression Systems is an important step in expanding ANGUS’ leadership position in Life Sciences beyond bio buffers into specialty cell culture media, a strategic adjacency with high customer overlap and complementary product and service offerings,” said ANGUS President and Chief Executive Officer David Neuberger. “The combination of ANGUS and Expression Systems further strengthens our ability to deliver value through the consistent, high-quality ingredients and services essential to all phases of bioprocessing, from early-stage biologics development to full-scale commercial production.”
Expression Systems is a well-recognized independent provider of specialized cell culture media and related products with a robust track record of product quality and innovation based on proprietary technology. The company specializes in baculovirus expression vector system (BEVS) and has deep expertise across the process from gene optimization to protein purification. Expression Systems’ products are utilized primarily by structural biology researchers and biologics manufacturers to produce certain drug candidates, protein-based therapies, vaccines and gene therapies efficiently and cost-effectively.
“For more than 20 years, our family and dedicated employees have built a strong reputation with its customers by leveraging our world-renowned technical expertise in media manufacturing and the baculovirus expression platform,” said Expression Systems President and Chief Executive Officer David Hedin. “When we looked ahead to the future for our company, it was clear that ANGUS was in the best position to provide new opportunities to our current and new customers, as well as our employees. ANGUS will enhance our position as a dedicated, world-leading vendor focused on servicing the biologics industry segments employing the baculovirus expression platform.”
Achelous Partners, LLC served as exclusive M&A advisor to Expression Systems, LLC on this transaction.